Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Keytruda Tops Japan Sales Ranking for 4th Month in January: Encise
February 7, 2024
- Sumitomo to Reinforce Restructuring to Fight Deficit, First in North America: President
February 6, 2024
- Astellas Slashes FY2023 Veozah Forecast as Vertical Start-Up Plan Stumbles
February 6, 2024
- Chugai’s 2023 Earnings Slip as Ronapreve Wanes, but Sales Still Top 1 Trillion Yen
February 2, 2024
- Chugai to Make Singapore Unit a Permanent Drug Discovery Research Base
February 2, 2024
- Takeda’s April-December Sales Up 4.6%, but Flat at CER
February 2, 2024
- Takeda Bags Global Rights to Protagonist’s Rare Hematology Asset
February 2, 2024
- Milano Furuta to Take Over as CFO of Takeda in April
February 2, 2024
- Cheplapharm Takes Over Xeloda from Chugai in Japan
February 2, 2024
- Cefiderocol Approved for Use in China’s Special Medical Tourism Zone: Shionogi
February 2, 2024
- Shionogi Sees 60% Ramp-Up in Medicon Output in FY2023
February 2, 2024
- Sumitomo to Cut Med- to Long-Term Guidance amid Tepid Uptake of New Drivers
February 1, 2024
- Astellas Links Arms with Mass General Brigham for Early R&D
February 1, 2024
- BMS Files Breyanzi in Japan for Expanded Use in Follicular Lymphoma
February 1, 2024
- Daiichi Sankyo Ups Full-Year Outlook on Growth of Flu, COVID Products
February 1, 2024
- Daiichi Sankyo Seeks Label Expansion for Ezharmia into PTCL in Japan
February 1, 2024
- Keytruda/Padcev Filed in Japan for 1st Line Bladder Cancer Treatment: MSD, Astellas
February 1, 2024
- Parmodia Again Tops December GP Rep Promotion Ranking, Dayvigo 5th Month Title Holder for HP
February 1, 2024
- Axcelead DDP Looks to Lift Overseas Sales Ratio to 80%: President
January 31, 2024
- Teva Takeda JVs Curb Shipments of 8 Products in Quake Fallout
January 31, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…